Vista rallied on an upbeat Forsyth Barr report.
CBA surge buoys Australia’s market.
Regulatory and policy issues in China and the US, which delivers 50% of revenues, have hit Australia’s largest listed biotech company's sales of vaccine and blood plasma products.
Vulcan led the benchmark higher on its latest broker upgrade.
Worse than expected trading has chewed into the carpet-maker’s cash reserves, lower the potential capital return to investors if a deal to sell the business goes through.
Skellerup marched higher on an upgrade by Craigs Investment Partners.
Bourns Inc has today made a formal offer to take over NZX-listed Rakon for $1.55 per share in an all-cash offer.
Expert panel finds adverse impacts of seabed mining project significantly outweighed economic benefits.
Heartland was one of the day’s rare gainers.
After four attempts, the companies have walked away from merger talks after failing to agree on price.
